Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.75 per share, better than the Zacks Consensus Estimate of a loss of$1.11, and improved from a loss of $0.98 per share a year ago, representing an earnings surprise of 32.43$132 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.86%, and compared to year-ago revenues of $119 million [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 14.7% since the beginning of the year, while the S&P 500 declined by 5.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of$146.33 million, and for the current fiscal year, it is -$3.31 on revenues of$637.57 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 20% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]